RADX vs RNW vs CWEN vs BEP

For growth investors, Radiopharm Theranostics Limited (RADX) is the stronger pick with 1114% revenue growth year-over-year, versus 4.

2% for Clearway Energy, Inc. (CWEN). Clearway Energy, Inc. (CWEN) offers the better valuation at 26. 9x trailing P/E, making it the more compelling value choice. Analysts rate ReNew Energy Global Plc (RNW) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Clearway Energy, Inc.

(CWEN) is the cheapest at 26. 9x versus ReNew Energy Global Plc at 46. 9x.

Over the past 5 years, Clearway Energy, Inc.

(CWEN) delivered a total return of +72. 5%, compared to -76. 5% for Radiopharm Theranostics Limited (RADX). Over 10 years, the gap is even starker: CWEN returned +237. 4% versus RADX's -76. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Clearway Energy, Inc.

(CWEN) is the lower-risk stock at 0. 54β versus Radiopharm Theranostics Limited's 0. 88β — meaning RADX is approximately 62% more volatile than CWEN relative to the S&P 500. On balance sheet safety, Brookfield Renewable Partners L. P. (BEP) carries a lower debt/equity ratio of 102% versus 6% for ReNew Energy Global Plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Radiopharm Theranostics Limited (RADX) is pulling ahead at 1114% versus 4.

2% for Clearway Energy, Inc. (CWEN). On earnings-per-share growth, the picture is similar: Brookfield Renewable Partners L. P. grew EPS 92. 4% year-over-year, compared to 10. 1% for ReNew Energy Global Plc. Over a 3-year CAGR, RADX leads at 643. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Clearway Energy, Inc.

(CWEN) is the more profitable company, earning 11. 8% net margin versus -1055. 3% for Radiopharm Theranostics Limited — meaning it keeps 11. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RNW leads at 53. 5% versus -1050. 6% for RADX. At the gross margin level — before operating expenses — RNW leads at 91. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for RNW: 20.

7% to $6. 52.

In this comparison, BEP (11.

7% yield), CWEN (7. 9% yield) pay a dividend. RADX, RNW do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Clearway Energy, Inc.

(CWEN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 54), 7. 9% yield, +237. 4% 10Y return). Both have compounded well over 10 years (CWEN: +237. 4%, RADX: -76. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (RADX (Healthcare) and RNW (Utilities) and CWEN (Utilities) and BEP (Utilities)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: RADX is a small-cap high-growth stock; RNW is a small-cap high-growth stock; CWEN is a small-cap income-oriented stock; BEP is a mid-cap income-oriented stock. CWEN, BEP pay a dividend while RADX, RNW do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.